250 related articles for article (PubMed ID: 23218705)
1. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Kang HM; Kim YM; Koh HJ
Am J Ophthalmol; 2013 Mar; 155(3):438-447.e1. PubMed ID: 23218705
[TBL] [Abstract][Full Text] [Related]
2. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Shirakata Y; Fujiwara A
Am J Ophthalmol; 2013 Jan; 155(1):96-102.e1. PubMed ID: 22995028
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
5. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
6. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
[TBL] [Abstract][Full Text] [Related]
8. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
Oishi A; Kojima H; Mandai M; Honda S; Matsuoka T; Oh H; Kita M; Nagai T; Fujihara M; Bessho N; Uenishi M; Kurimoto Y; Negi A
Am J Ophthalmol; 2013 Oct; 156(4):644-51. PubMed ID: 23876867
[TBL] [Abstract][Full Text] [Related]
10. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
11. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
12. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
13. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
14. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters.
Lee WK; Kim KS; Kim W; Lee SB; Jeon S
Am J Ophthalmol; 2012 Aug; 154(2):355-365.e1. PubMed ID: 22541658
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
18. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.
Chan WM; Liu DT; Lai TY; Li H; Tong JP; Lam DS
Clin Exp Ophthalmol; 2005 Dec; 33(6):611-8. PubMed ID: 16402954
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
